Drugs / BC 007
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02955420 | Aug 2016 → Apr 2018 | — | Berlin Cures GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05911009 | Jun 2023 → Jun 2024 | long COVID-19 | Berlin Cures GmbH | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04192214 Comparator | Mar 2019 → Dec 2022 | autoimmune disease, dilated cardiomyopathy, heart failure | Berlin Cures GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC 007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05911009 ↗ |
| Route | Intravenous | “single intravenous infusions of increasing concentration were given to healthy young males and healthy elderly autoantibody-negative and autoantibody-positive participants of...” PMID 32222912 ↗ May 2020 |